Skip to content

Dr. Barry Dworkin

  • About
  • Radio Interviews
    • Wednesday House Call
    • Sunday House Call Shows
  • Articles
    • Health Headlines
    • Prevention and Screening
    • Clinical Research
    • Health Policy
    • Cancer/Oncology
    • Neurology
  • Glp-1 medications like semaglutide (Ozempic, Wegovy)) and Tirzepatide (Mounjaro, Zepbound) are designed for long-term use to treat chronic disease/conditions. What happens if people go on and off them?

    October 29, 2026

    Medical Mythbusting Commentary for October 30, 2026 Source:Everyone’s going on — and off — GLP-1s. What’s that doing to your health?

  • The aging process and its effect on fertility

    October 28, 2026

    Medical Mythbusting Commentary for October 28, 2026 Source:Delayed motherhood and the biological clock: What women need to know

  • More evaluation required to determine the degree menopause contributes to the greater incidence of dementia in women.

    October 27, 2026

    Medical Mythbusting Commentary for October 27, 2026 Source:Clues to higher incidence of dementia in women may lie in menopause

  • Visceral Fat, Not Aging, May Be The Real Driver of Low Testosterone

    October 14, 2026

    Medical Mythbusting Commentary for October 14, 2026 Source:Visceral Fat, Not Aging, May Be The Real Driver of Low Testosterone Reference:Low testosterone is a phenotype of visceral adiposity

  • Too many confounding factors to conclude that there is an association between melatonin use and increased congestive heart failure risk

    September 8, 2026

    Medical Mythbusting Commentary for September 8, 2026 Source:Melatonin Use Linked to Massively Increased Risk of Heart Failure Reference:Long-term melatonin use linked to 90% higher heart failure risk

  • Mass testosterone screening of healthy male military personnel is not based on clinical evidence or guidelines and is unlikely to change battle readiness or health outcomes.

    September 4, 2026

    Medical Mythbusting Commentary for September , 2026 Source:Pentagon issues clinical guidelines on troop testosterone screening to start immediately Reference:The CTV piece is a Reuters write-up of Defense Health Agency clinical guidance issued 2 September 2026. That guidance implements Secretary Hegseth’s 15 July 2026 memo requiring mandatory testosterone-deficiency screening for all active-duty and reserve members aged…

  • Targeted gene-altering therapy reduced LDL-cholesterol levels by 50 per cent in patients with severely elevated cholesterol levels.

    September 2, 2026

    Medical Mythbusting Commentary for September 2, 2026 Source:With the snip of a gene, scientists hope to erase high cholesterol for life Reference:Phase 1 Trial of CRISPR-Cas9 Gene Editing Targeting ANGPTL3

  • Phase 1 targeted gene editing study demonstrates safety and reduction in LDL cholesterol levels through specific protein pathway

    August 17, 2026

    Medical Mythbusting Commentary for August 17, 2026 Source:‘An extremely exciting milestone!’: landmark treatment slashes cholesterol by 62% with a single dose Reference:In Vivo Base Editing of PCSK9 with VERVE-102 for Hypercholesterolemia

  • PCOS (polycystic ovary syndrome), which affects tens of millions of women, is now known as PMOS (polyendocrine metabolic ovarian syndrome)to better reflect what it actually represents.

    May 14, 2026

    Medical Mythbusting Commentary for May 14, 2026 Source:PCOS, which affects tens of millions of women, is now known as PMOS. Here’s why the renaming is important Reference:Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process

  • Facebook
  • X